EXETF Company Profile and Key Details

Average 10-day trading volume of 4.80 thousand shares is significantly above the 3-month average of 2.21 thousand, indicating heightened recent market interest.

Extendicare Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 100.93%. The prior quarter beat by 8.04%. Over the last six quarters, Apple has recorded several small beats. These include 21.47% in February 27, 2025.

Extendicare Inc. last paid a dividend of 0.37 per share, this equals a trailing yield of roughly 4.88%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.27. This means the shares are trading above this model’s fair value.

Extendicare Inc. (OTC:EXETF) closed at $24.14 USD, losing -$0.18 (-0.74%) from the previous close of $24.32. The stock is currently mid-range between its 52-week high and low $8.62 and $25.95. With a market capitalization of about $2.29 billion, Extendicare Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.92). Key stats such as the average daily volume over the past year has been around 2.87 thousand shares, volume is running light vs its 52-week average. Headquartered in Markham, ON, Extendicare Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO David E. Bacon, the company employs approximately 23,500 people and listed since January 10, 2007. Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada.

Valuation shows Extendicare Inc. trading at a premium to the broader market with a P/E of 25.71.

Our AI price prediction model suggests that Extendicare Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Extendicare Inc. trades at a P/E ratio of 25.71, slightly below the S&P 500 average, with a price-to-sales ratio of 1.79 and a price-to-book ratio of 7.99 trading at moderately above to book value. The P/FCF stands at 63.56, also above market averages.